title: [Leishmaniasis--oral treatment with hexadecylphosphocholine].
abstract: Hexadecylphosphocholine (HDPC, Miltefosine, Impavido) was synthesized at the Max-Planck-Institut für Biophysikalische Chemie in Göttingen, Germany and successfully used for the therapy of cancer metastases. At the Institute of General and Tropical Hygiene of Göttingen University the antiparasitic efficacy--earlier mentioned by Croft et al. (1987)--could be established for the first time in animals after oral administration. In India Impavido has been recently registered for the treatment of visceral leishmaniasis as the first oral medication in this indication. Clinical studies in India--actually a phase IV study is running--and Columbia (cutaneous leishmaniosis) demonstrated the excellent efficacy of this oral treatment also in patients with Antimon resistance. The cure rates are above 90% with low side effects (Impavido twice 50 mg capsules daily over 28 days).
authors.affiliation: Institut für Allgemeine Hygiene der Universität Göttingen/Tropenmedizinisches Beratungszentrum, Göttingen, Deutschland. info@labor-wagnerstibbe.de
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Bommer
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Eibl
authors.forename: Kirsten R
authors.initials: KR
authors.lastname: Engel
authors.forename: Armin
authors.initials: A
authors.lastname: Kuhlencord
authors.forename: Herbert
authors.initials: H
authors.lastname: Sindermann
authors.forename: Sham
authors.initials: S
authors.lastname: Sundar
authors.forename: Hildegard
authors.initials: H
authors.lastname: Zappel
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy; D007898:Leishmaniasis, Visceral / Q000188:drug therapy; D015201:Meta-Analysis as Topic; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine